Author | Batista, Cassiano Martin | |
Author | Foti, Leonardo | |
Access date | 2021-11-12T17:08:03Z | |
Available date | 2021-11-12T17:08:03Z | |
Document date | 2021 | |
Citation | BATISTA, Cassiano Martin. et al. Anti-SARS-CoV-2 and anti-cytokine storm neutralizing antibody therapies against COVID-19: Update, challenges, and perspectives. Stem Cells International. v.99, n. 108036, p. 1–10, 2021. | pt_BR |
ISSN | 1567-5769 | pt_BR |
URI | https://www.arca.fiocruz.br/handle/icict/49819 | |
Language | por | pt_BR |
Publisher | Elsevier | pt_BR |
Rights | open access | pt_BR |
Subject in Portuguese | SARS-CoV-2 | pt_BR |
Subject in Portuguese | COVID-19 | pt_BR |
Subject in Portuguese | SPIKE | pt_BR |
Subject in Portuguese | Imunoterapia Passiva | pt_BR |
Subject in Portuguese | Tempestade de Citocinas | pt_BR |
Title | Anti-SARS-CoV-2 and anti-cytokine storm neutralizing antibody therapies against COVID-19: Update, challenges, and perspectives | pt_BR |
Type | Article | pt_BR |
DOI | 10.1016/j.intimp.2021.108036 | |
Abstract | Coronavirus disease 2019 (COVID-19) has been declared by the World Health Organization (WHO) as a
pandemic since March 2020. This disease is caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV-2). The only available tools to avoid contamination and transmission of this virus are physical distancing, the use of N95 and surgical masks, and hand hygiene. Vaccines are another essential tool to reduce the impact of the pandemic, though these present challenges in terms of production and logistics, particularly in underdeveloped and developing countries. One of the critical early research findings is the interaction of the spike virus protein with the angiotensin-converting enzyme 2 (ACE2) human receptor. Developing strategies to block this interaction has therefore been identified as a way to treat this infection. Neutralizing antibodies (nAbs) have emerged as a therapeutic approach since the pandemic started. Infected patients may be asymptomatic or present with mild symptoms, and others may evolve to moderate or severe disease, leading to death. An immunological phenomenon known as cytokine storm has been observed in patients with severe disease characterized by a proinflammatory cytokine cascade response that leads to lung injury. Thus, some treatment strategies focus on anti-cytokine storm nAbs. This review summarizes the latest advances in research and clinical trials, challenges, and perspectives on antibody-based treatments (ABT) as therapies against COVID-19. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Biologia Molecular e Sistêmica de Tripanossomatídeos. Curitiba, PR, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Biologia Molecular e Sistêmica de Tripanossomatídeos. Curitiba, PR, Brasil. | pt_BR |
Subject | Spike Glycoprotein, Coronavirus | pt_BR |
Subject | Immunization, Passive | pt_BR |
Subject | Antibodies, Neutralizing | pt_BR |
Subject | Cytokine Release Syndrome | pt_BR |
Subject in Spanish | Glicoproteína de la Espiga del Coronavirus | pt_BR |
Subject in Spanish | Inmunización Pasiva | pt_BR |
Subject in Spanish | Anticuerpos Neutralizantes | pt_BR |
Subject in Spanish | Síndrome de Liberación de Citoquinas | pt_BR |
Subject in French | Glycoprotéine de spicule des coronavirus | pt_BR |
Subject in French | Immunisation passive | pt_BR |
Subject in French | Anticorps neutralisants | pt_BR |
DeCS | Glicoproteína da Espícula de Coronavírus | pt_BR |
DeCS | Imunização Passiva | pt_BR |
DeCS | Anticorpos Neutralizantes | pt_BR |
DeCS | Síndrome da Liberação de Citocina | pt_BR |